REQUEST A DEMO
Total
USD $0.00
Search more companies

Ibsa Ilac San. Ve Tic. Ltd. Sti. (Turkiye)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Ibsa Ilac Sanayi Ve Ticaret Limited Sirketi Profile Updated: September 09, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Ibsa Ilac Sanayi Ve Ticaret Limited Sirketi is a multinational pharmaceutical company. The company operates in the reproductive medicine area and offers a portfolio of products for the treatment of infertility, including progesterone in aqueous solution and extractive gonadotropins. They also offer hyaluronic acid-based products in pre-filled syringes and soft capsules for urothelium health, as well as an innovative oral formulation for Erectile Dysfunction. Ibsa Ilac Sanayi Ve Ticaret Limited Sirketi operates in over 90 countries on 5 continents with 18 subsidiaries in Europe, China, and the United States.

Headquarters
Torun Center D Blok Apartmani No:74 D-5 Fulya Mahallesi Buyukdere Caddesi Sisli
Istanbul; Marmara; Postal Code: 34394

Contact Details: Purchase the Ibsa Ilac San. Ve Tic. Ltd. Sti. report to view the information.

Website: http://www.ibsa.com.tr

Basic Information
Total Employees:
Purchase the Ibsa Ilac San. Ve Tic. Ltd. Sti. report to view the information.
Outstanding Shares:
Purchase the Ibsa Ilac San. Ve Tic. Ltd. Sti. report to view the information.
Incorporation Date:
March 15, 2007
Key Executives
Purchase this report to view the information.
Company Manager
Company Performance
Financial values in the chart are available after Ibsa Ilac San. Ve Tic. Ltd. Sti. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TRY. Absolute financial data is included in the purchased report.
Net sales revenue
164.18%
Total operating revenue
164.18%
Operating profit (EBIT)
393.84%
Net Profit (Loss) for the Period
194.93%
Total assets
51.42%
Total equity
69.89%
Operating Profit Margin (ROS)
8.19%
Net Profit Margin
1.49%
Return on Equity (ROE)
17.44%
Debt to Equity Ratio
-20.8%
Quick Ratio
0.91%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?